论文部分内容阅读
目的分析阿德福韦酯联合拉米夫定治疗乙型肝炎(乙肝)肝硬化失代偿期的疗效。方法 80例乙肝肝硬化失代偿期患者,将其随机分为对照组和治疗组,各40例,两组患者均实行保肝、利尿等基础治疗,对照组患者在实行基础治疗的同时服用拉米夫定,而治疗组则在基础治疗的同时服用阿德福韦酯和拉米夫定。观察治疗3个月后两组的肝功能和出凝血时间变化情况。结果两组患者经过治疗后,肝功能和出凝血时间均得到有效改善,同时治疗组的疗效明显优于对照组(P<0.05),两组治疗后均未出现不良反应。结论阿德福韦酯联合拉米夫定治疗乙肝肝硬化失代偿期的疗效显著,安全可靠,值得进一步推广应用。
Objective To analyze the efficacy of adefovir dipivoxil combined with lamivudine in the treatment of decompensated liver cirrhosis (Hepatitis B). Methods 80 patients with decompensated hepatitis B cirrhosis were randomly divided into control group and treatment group, 40 cases in each group. Both groups received basic treatment such as liver protection and diuresis. Patients in control group received basic treatment while taking Lamivudine, while the treatment group was taking adefovir dipivoxil and lamivudine at the same time as the basic treatment. The changes of liver function and coagulation time in the two groups after 3 months of treatment were observed. Results After treatment, the liver function and the clotting time of both groups were effectively improved. At the same time, the curative effect of the treatment group was obviously better than that of the control group (P <0.05). No adverse reactions occurred in both groups after treatment. Conclusion adefovir dipivoxil combined with lamivudine treatment of hepatitis B cirrhosis decompensated significant effect, safe and reliable, it is worth further promotion and application.